Global Supplement Compliance: Navigating Divergent UK, EU, and US Regulatory Frameworks

Navigating the international dietary supplement landscape requires contract manufacturers, formulators, and brand owners to manage increasingly fragmented regulatory environments. While commercial demand for botanical extracts, functional ingredients, and specialised micronutrient delivery formats remains global, the statutory mechanisms governing product safety, novel ingredients, and commercial communications remain strictly regional. For companies operating across the United Kingdom, the European Union, and the United States, regulatory compliance dictates every stage of product development, from raw material qualification to finished pack labelling. ## Divergence in Novel Food and Ingredient Authorisation A critical technical divergence between markets involves the definition and administration of novel food status. In the UK and the EU, substances without a demonstrable history of significant consumption prior to 15 May 1997 fall under novel food regimes administered by the Food Standards Agency (FSA) and the European Commission (advised by the European Food Safety Authority, EFSA), respectively. Following the UK's withdrawal from the EU, the FSA maintains an independent regulated products application service. While both jurisdictions evaluate safety via toxicological dossiers, exposure assessments, and stability data, review timelines and ingredient authorisations have decoupled. Formulators must note that a novel food authorisation granted by the European Commission does not apply in Great Britain (GB), requiring separate submissions, validation, and risk assessment through the FSA. Conversely, the US regulatory framework, overseen by the Food and Drug Administration (FDA) under the Dietary Supplement Health and Education Act of 1994 (DSHEA), relies on either Old Dietary Ingredient (ODI) status or New Dietary Ingredient (NDI) notifications. Unlike the pre-market approval system common to European novel foods, the US NDI process requires manufacturers to submit safety documentation at least 75 days prior to commercial introduction, unless the ingredient has achieved self-affirmed or notified Generally Recognised as Safe (GRAS) status for the intended use. ## Analytical Verification and Good Manufacturing Practice Quality assurance across jurisdictions requires adherence to distinct Good Manufacturing Practice (GMP) standards. In the US, finished-product manufacturers and packagers must conform to 21 CFR Part 111, which mandates comprehensive identity testing for all incoming dietary ingredients alongside documented process controls and batch production records. In the UK and EU, supplement manufacturing is primarily governed by general food hygiene legislation, notably Regulation (EC) No 852/2004, alongside Codex Alimentarius principles. However, commercial retail standards across Europe routinely demand third-party GFSI-recognised certifications, such as BRCGS or IFS, to satisfy supply-chain due diligence and supplier qualification protocols. Analytical compliance also extends to contaminant monitoring. Discrepancies exist between statutory maximum limits for heavy metals (lead, cadmium, arsenic, and mercury), ethylene oxide residues, and pesticide thresholds. For instance, EU regulations under Regulation (EU) 2023/915 establish strict maximum residue limits for heavy metals in food supplements. In contrast, US compliance intersects with federal food adulteration safety profiles alongside state-level statutory thresholds, most notably California Proposition 65 safe harbour levels, which often mandate warning labels at significantly lower thresholds than federal limits. ## Substantiation and Permissible Health Claims Commercial claims represent another operational challenge for technical and regulatory affairs teams. In the EU and UK, nutrition and health claims are subject to the framework established under Regulation (EC) No 1924/2006 (retained in UK law for GB). Only pre-authorised health claims included in the respective statutory registers may appear on commercial packaging and secondary marketing. Authorisation by the European Commission or UK ministers requires robust human clinical intervention data demonstrating a cause-and-effect relationship between the specific nutrient or substance and the claimed physiological benefit. Generic botanical claims remain largely 'on hold' in both jurisdictions, leaving brand owners reliant on national transitional measures or traditional-use frameworks where permitted. In contrast, the US FDA permits structure/function claims without pre-market clinical dossier approval, provided the claim is truthful, non-misleading, and accompanied by the mandatory statutory disclaimer stating that the product is not intended to diagnose, treat, cure, or prevent any disease. US brand owners must notify the FDA within 30 days of initial commercialisation and maintain competent and reliable scientific evidence to substantiate all claims prior to distribution.